Biggest FDA News for Multiple Myeloma in 2021

Video

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

Nina Shah, MD: The biggest FDA news that we got this year was the approval of ide-cel [idecabtagene vicleucel; Abecma]. The reason it’s a big deal for us is that it now changes how we think about our lines 1, 2, 3, and 4, approaching a patient with multiple myeloma, and it allowed us to start getting our hands wet with how to use this and the logistics of that. It’s going to change how we, for example, have apheresis spots in our clinics or what kind of referral patterns we have in the community. It was nice to get that approval to start the ball rolling to hopefully bring this therapy to more patients.

Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
3 experts in this video
3 experts in this video
2 experts are featured in this series.
9 Experts are featured in this series.
Related Content
Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

Data Support Real-World Use of Ide-cel in R/R CNS Multiple Myeloma

Jonah Feldman
December 12th 2024
Article

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM

Overall MRD Negativity Rates Improved with Cilta-cel vs SOC in MM

Jordyn Sava
December 10th 2024
Article

In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma

Superior Rates of MRD Upheld by Isatuximab Combo in Multiple Myeloma

Silas Inman
December 10th 2024
Article

Patients with newly diagnosed multiple myeloma experienced sustained MRD negativity with isatuximab/bortezomib/lenalidomide/dexamethasone.

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Regimen Improves OS in R/R Multiple Myeloma

Kristi Rosa
December 10th 2024
Article

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.